A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma
Valli De Re,
Laura Caggiari,
Maurizio Mascarin,
Mariangela De Zorzi,
Caterina Elia,
Ombretta Repetto,
Lara Mussolin,
Marta Pillon,
Paola Muggeo,
Salvatore Buffardi,
Maurizio Bianchi,
Alessandra Sala,
Luciana Vinti,
Piero Farruggia,
Elena Facchini,
Egesta Lopci,
Emanuele S. G. d’Amore,
Roberta Burnelli,
with the A.I.E.O.P. Consortium
Affiliations
Valli De Re
Immunopathology and Cancer Biomarkers—Bio-Proteomics Facility, CRO Aviano National Cancer Institute, 33081 Aviano, Italy
Laura Caggiari
Immunopathology and Cancer Biomarkers—Bio-Proteomics Facility, CRO Aviano National Cancer Institute, 33081 Aviano, Italy
Maurizio Mascarin
Centro di Riferimento Oncologico di Aviano (CRO), AYA Oncology and Pediatric Radiotherapy Unit, IRCCS, 33081 Aviano, Italy
Mariangela De Zorzi
Immunopathology and Cancer Biomarkers—Bio-Proteomics Facility, CRO Aviano National Cancer Institute, 33081 Aviano, Italy
Caterina Elia
Centro di Riferimento Oncologico di Aviano (CRO), AYA Oncology and Pediatric Radiotherapy Unit, IRCCS, 33081 Aviano, Italy
Ombretta Repetto
Immunopathology and Cancer Biomarkers—Bio-Proteomics Facility, CRO Aviano National Cancer Institute, 33081 Aviano, Italy
Lara Mussolin
Pediatric Hemato-Oncology Clinic, Department of Women’s and Children’s Health, Institute of Pediatric Research—Fondazione Città Della Speranza, University of Padua, 35127 Padua, Italy
Marta Pillon
Pediatric Hemato-Oncology Clinic, Department of Women’s and Children’s Health, Institute of Pediatric Research—Fondazione Città Della Speranza, University of Padua, 35127 Padua, Italy
Paola Muggeo
Department of Pediatric Hemato-Oncology, University of Bari, 70124 Bari, Italy
Several studies have examined the prognostic performance of therapeutic groups (TG) and early responses to therapy on positron emission tomography/computed tomography (PET/CT) in children and adolescents with classical Hodgkin lymphoma (cHL); less research has been performed on molecular parameters at diagnosis. The aim of the present study was to devise a scoring system based on the TG criteria for predicting freedom from progression (FFP) in 133 patients: 63.2% males; 14 years median age (interquartile range (IQR) 11.9–15.1); with cHL (108 nodular sclerosis (NS) subtype) treated according to the AIEOP LH-2004 protocol; and median 5.55 (IQR 4.09–7.93) years of follow-up. CHL progressed or relapsed in 37 patients (27.8%), the median FFP was 0.89 years (IQR = 0.59–1.54), and 14 patients (10.5%) died. The FPR (final prognostic rank) model associates the biological HLA-G SNP 3027C/A (numerical point assigned (pt) = 1) and absolute neutrophil count (>8 × 109/L, pt = 2) as variables with the TG (TG3, pt = 3). Results of FPR score analyses for FFP suggested that FPR model (Kaplan–Meier curves, log-rank test for trends) was better than the TG model. At diagnosis, high-risk patients classified at FPR rank 4 and 5 identified 18/22 patients who relapse during the follow-up.
